ArticleMarine drugs2015
Cytotoxic and antibacterial angucycline- and prodigiosin-analogues from the deep-sea derived Streptomyces sp. SCSIO 11594.
Article in Marine drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- NewTheScientificWorldJournal · 2025Pooled it
- A novel Umezawaea tangerina endophyte reveals anti-colorectal cancer activity and a rich biosynthetic landscape.Scientific reports · 2026Article
- Identification of SARS-CoV-2 3CLpro inhibitors from marine actinomycetes through integrated phylogeny-based metabolomics with functional screening and bioinformatic analysis.Scientific reports · 2025Article
- Salt-Adapted Microorganisms: A Promising Resource for Novel Anti-Cancer Drug Discovery.Marine drugs · 2025Review
- Structural characterization, derivatization, and bioactivities of secondary metabolites produced by termite-associatedMicrobiology spectrum · 2025Article
- Bioactive Angucyclines/Angucyclinones Discovered from 1965 to 2023.Marine drugs · 2025Review
- Characterization and Bioactive Metabolite Profiling ofMicroorganisms · 2024Article
- Decylprodigiosin: a new member of the prodigiosin family isolated from a seaweed-associatedFrontiers in pharmacology · 2024Article
- Bacterial Pigments and Their Multifaceted Roles in Contemporary Biotechnology and Pharmacological Applications.Microorganisms · 2023Review
- Structures, biosynthesis, and bioactivities of prodiginine natural products.Applied microbiology and biotechnology · 2022Review
- Recent Advances on Natural Aryl-Molecules (Basel, Switzerland) · 2022Review
- Marine Actinobacteria a New Source of Antibacterial Metabolites to Treat Acne Vulgaris Disease-A Systematic Literature Review.Antibiotics (Basel, Switzerland) · 2022Review
- Investigating Alkylated Prodigiosenes and Their Cu(II)-Dependent Biological Activity: Interactions with DNA, Antimicrobial and Photoinduced Anticancer Activity.ChemMedChem · 2022Article
- Cytotoxic compounds from marine actinomycetes: Sources, Structures and Bioactivity.Acta materia medica · 2022Article
- Integrated Metabolomic, Molecular Networking, and Genome Mining Analyses Uncover Novel Angucyclines FromFrontiers in microbiology · 2022Article
- Complete Genome Analysis of Undecylprodigiosin Pigment Biosynthesizing MarineMicroorganisms · 2021Article
- Marine Anthraquinones: Pharmacological and Toxicological Issues.Marine drugs · 2021Review
- An Overview on Industrial and Medical Applications of Bio-Pigments Synthesized by Marine Bacteria.Microorganisms · 2020Review
- Chlorinated bis-indole alkaloids from deep-sea derived Streptomyces sp. SCSIO 11791 with antibacterial and cytotoxic activities.The Journal of antibiotics · 2020Article
- Metagenomics Approaches in Discovery and Development of New Bioactive Compounds from Marine Actinomycetes.Current microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two new C-glycoside angucyclines, marangucycline A (1) and marangucycline B (2), along with three known compounds, dehydroxyaquayamycin (3), undecylprodigiosin (4) and metacycloprodigiosin (5), have been identified as products of the deep-sea sediment strain Streptomyces sp. SCSIO 11594. New structures were elucidated on the basis of HRESIMS, 1D and 2D NMR analyses and comparisons to previously reported datasets. Compounds 2 and 4 displayed in vitro cytotoxicity against four cancer cell lines A594, CNE2, HepG2, MCF-7 superior to those obtained with cisplatin, the positive control. Notably, compound 2 bearing a keto-sugar displayed significant cytotoxicity against cancer cell lines with IC50 values ranging from 0.24 to 0.56 μM; An IC50 value of 3.67 μM was found when using non-cancerous hepatic cell line HL7702, demonstrating the cancer cell selectivity of 2. Compounds 1-3 were proved to have weak antibacterial activities against Enterococcus faecalis ATCC29212 with an MIC value of 64.0 μg/mL. Moreover, 3 displayed selective antibacterial activity against methicillin-resistant Staphylococcus epidermidis shhs-E1 with an MIC value of 16.0 μg/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.